Modulation of TDM-induced granuloma pathology by human lactoferrin: a persistent effect in mice

Jeffrey K Actor1, Thao K T Nguyen2, Agnieszka Wasik-Smietana3

  • 1Department of Pathology and Laboratory Medicine, UTHealth McGovern Medical School, MSB 2.214, 6431 Fannin, Houston, TX, 77030, USA. Jeffrey.K.Actor@uth.tmc.edu.

Insights

Lactoferrin (LTF) and FcLTF treatments reduced lung inflammation and pathology in mouse models of Mycobacterium tuberculosis infection. FcLTF showed superior efficacy in limiting tissue damage and residual cytokine production.

Area of Science:

  • Immunology
  • Pulmonary Pathology
  • Infectious Diseases

Background:

  • Lactoferrin (LTF) modulates immune responses in lung pathology during Mycobacterium tuberculosis (Mtb) infection.
  • Recombinant human LTF limits granulomatous severity and pro-inflammatory responses after Mtb component TDM administration.

Purpose of the Study:

  • To investigate the effects of a limited course of LTF on the initiation, maintenance, and resolution of lung granuloma pathology.
  • To compare the efficacy of LTF with a fusion protein, FcLTF, which has an extended circulation half-life.

Main Methods:

  • Mice were treated with LTF or FcLTF after TDM-induced granuloma formation.
  • Lung granulomas were examined at days 7 and 14 post-insult.
  • Pro-inflammatory cytokines (TNF-α, IL-1β) and IL-6 levels were measured.

Main Results:

  • Both LTF and FcLTF demonstrated sustained effects on lung granuloma pathology.
  • Treatment reduced pulmonary pro-inflammatory cytokines TNF-α and IL-1β.
  • IL-6 levels increased, indicating a role in granuloma maintenance. FcLTF showed greater efficacy than LTF.

Conclusions:

  • LTF and FcLTF treatments effectively modulate lung granuloma pathology in Mtb infection models.
  • FcLTF is superior to LTF in limiting pulmonary tissue damage and residual inflammation.
  • These findings suggest potential therapeutic applications for LTF and FcLTF in tuberculosis treatment.

Related Concept Videos